Abingworth LLP

13F Portfolio Filings

Latest 13F report
Q2 2024 - Aug 9, 2024
Signature - Title
John Heard - General Counsel
Location
38 Jermyn Street, London, United Kingdom
Holdings Value

Carlyle Group Inc. is reporting for Abingworth LLP:

Name Holdings Value Location File Number
Carlyle Group Inc. $1.05B Washington, District Of Columbia 028-15025
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q2 2024 13F-NT 8/9/2024, 04:47 PM
Q1 2024 13F-NT 5/3/2024, 04:39 PM
Q4 2023 0 13F-NT 2/2/2024, 04:47 PM
Q3 2023 0 13F-NT 11/3/2023, 04:44 PM
Q2 2023 0 13F-NT 8/4/2023, 04:41 PM
Q1 2023 0 13F-NT 5/5/2023, 05:01 PM
Q4 2022 19 $304M $0 -$103M -$103M PCVX, VRNA, VERA, HLVX, ACET 13F-HR 2/10/2023, 04:28 PM
Q3 2022 19 $292M +$4.92M -$79.2M -$74.2M PCVX, VERA, HLVX, ACET, VRNA 13F-HR 11/10/2022, 04:48 PM
Q2 2022 21 $312M +$19.9M -$14.7M +$5.25M PCVX, SRRA, VERA, ACET, HLVX 13F-HR 8/15/2022, 06:30 AM
Q1 2022 20 $352M +$18.9M $0 +$18.9M PCVX, VERA, ACET, SRRA, JSPRXXXX 13F-HR 5/16/2022, 07:00 AM
Q4 2021 20 $413M +$8.72M $0 +$8.72M PCVX, VERA, JSPRXXXX, EFTR, ACET 13F-HR 2/16/2022, 11:26 AM
Q3 2021 20 $441M +$126M -$1.73M +$124M PCVX, EFTR, JSPRXXXX, VERA, PHAT 13F-HR 11/15/2021, 06:05 AM
Q2 2021 19 $324M +$56.7M $0 +$56.7M PCVX, PHAT, VERA, SIENXXXX, RPHM 13F-HR 8/16/2021, 06:30 AM
Q1 2021 17 $290M +$22.9M $0 +$22.9M PCVX, PHAT, ACET, VRNA, SIENXXXX 13F-HR 5/17/2021, 06:11 AM
Q4 2020 15 $292M +$43.1M -$119M -$75.7M PCVX, PHAT, SLNO, VRNA, NCNA 13F-HR 3/1/2021, 11:18 AM
Q3 2020 17 $468M +$27.3M -$43.1M -$15.8M PCVX, PSNL, PHAT, SLNO, CRSP 13F-HR 11/16/2020, 06:15 AM
Q2 2020 15 $355M +$139M -$3.97M +$135M PCVX, PSNL, PHAT, CRSP, SLNO 13F-HR 8/14/2020, 03:27 PM
Q1 2020 16 $151M +$9.09M -$879K +$8.21M PSNL, PHAT, CRSP, SLNO, XCUR 13F-HR 5/14/2020, 06:05 AM
Q4 2019 16 $207M +$48.9M -$6.65M +$42.3M PSNL, PHAT, CRSP, SIENXXXX, SLNO 13F-HR 2/14/2020, 06:05 AM
Q3 2019 14 $158M +$15.8M -$38M -$22.3M PSNL, CRSP, XCUR, SIENXXXX, SLNO 13F-HR 11/14/2019, 06:06 AM
Q2 2019 14 $261M +$148M -$13.8M +$134M PSNL, CRSP, SIENXXXX, AVDR, SLNO 13F-HR 8/14/2019, 06:09 AM
Q1 2019 14 $112M +$13.4M -$12.5M +$856K CRSP, SIENXXXX, CHMA, SLNO, AVDR 13F-HR 5/15/2019, 06:15 AM
Q4 2018 16 $110M +$7.98M -$4.32M +$3.67M CRSP, SIENXXXX, VRNA, SLNO, CHMA 13F-HR 2/14/2019, 06:16 AM
Q3 2018 16 $168M +$11.3M -$11.9M -$644K CRSP, SIENXXXX, VRNA, PRTK, OBSVF 13F-HR 11/14/2018, 06:15 AM
Q2 2018 16 $175M +$7.22M -$38.8M -$31.5M CRSP, SIENXXXX, PRTK, OBSVF, GTXI 13F-HR 8/14/2018, 07:00 AM
Q1 2018 16 $161M +$2.98M -$18.1M -$15.1M CRSP, SIENXXXX, PRTK, GTXI, OBSVF 13F-HR 5/15/2018, 06:08 AM
Q4 2017 17 $138M $0 -$4.44M -$4.44M CRSP, SIENXXXX, PRTK, CBAY, OBSVF 13F-HR 2/14/2018, 06:10 AM
Q3 2017 18 $144M +$8.61M -$16.8M -$8.22M CRSP, SIENXXXX, PRTK, CBAY, CHMA 13F-HR 11/14/2017, 06:13 AM
Q2 2017 16 $126M $0 -$3.45M -$3.45M CRSP, PRTK, SIENXXXX, CBAY, CASC 13F-HR 8/14/2017, 06:02 AM
Q1 2017 17 $134M +$6.72M -$1.9M +$4.83M CRSP, PRTK, SIENXXXX, CBAY, CASC 13F-HR 5/15/2017, 07:36 AM
Q4 2016 16 $118M +$53.2M -$13.7M +$39.5M CRSP, PRTK, SIENXXXX, NOVNXXXX, CHMA 13F-HR 2/14/2017, 06:04 AM
Q3 2016 20 $104M +$4.8M -$7.61M -$2.82M SIENXXXX, PRTO, PRTK, CEMP, CHMA 13F-HR 11/14/2016, 07:20 AM
Q2 2016 20 $95.5M +$4.78M -$533K +$4.25M PRTK, PRTO, SIENXXXX, TBRA, CEMP 13F-HR 8/12/2016, 06:03 AM
Q1 2016 19 $108M +$256K $0 +$256K PRTK, CHMA, PRTO, SIENXXXX, CEMP 13F-HR 5/13/2016, 06:16 AM
Q4 2015 18 $166M +$6.11M -$369K +$5.74M CHMA, PRTO, PRTK, SIENXXXX, CEMP 13F-HR 2/16/2016, 07:22 AM
Q3 2015 17 $171M +$46.1M -$21.1M +$25M CHMA, PRTO, PRTK, SIENXXXX, EVAR 13F-HR 11/13/2015, 06:49 AM
Q2 2015 15 $216M +$19M -$47.5M -$28.6M SIENXXXX, PRTO, PRTK, AMRN, EVAR 13F-HR 8/14/2015, 06:47 AM
Q1 2015 17 $235M +$1.02M -$157M -$156M SIENXXXX, PRTK, SUPN, DRNA, PRTO 13F-HR 5/14/2015, 06:03 AM
Q4 2014 16 $352M +$108M -$56K +$108M RNA, PRTK, SIENXXXX, PTLA, SUPN 13F-HR 2/13/2015, 06:12 AM
Q3 2014 13 $167M +$25.7M -$14.2M +$11.5M RNA, EVAR, SUPN, PTLA, DRNA Restatement 11/25/2014, 03:07 PM
Q2 2014 12 $215M +$1.58M -$7.63M -$6.05M RNA, SUPN, PTLA, DRNA, AMRN 13F-HR 8/14/2014, 06:53 AM
Q1 2014 13 $181M +$36.3M $0 +$36.3M RNA, DRNA, SUPN, PTLA, AMRN 13F-HR 5/20/2014, 06:33 PM
Q4 2013 11 $133M $0 $0 PTLA, RNA, SUPN, AMRN, CEMP 13F-HR 2/14/2014, 08:47 AM